Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives – Yahoo Finance

npressfetimg-54.png

VANCOUVER, BC, Sept. 22, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h.

Nirvana Life Sciences Inc. Logo (CNW Group/Nirvana Life Sciences Inc.)

Nirvana Life Sciences Inc. is pleased to announce it has recently filed a patent for the deuterated form of 7-hydroxymitragynine (D7-h), the active compound in kratom responsible for the opiate like effect the plant produces when ingested. Opioid use disorder and opioid addiction remain at epidemic levels in Canada, the US and worldwide.  In 2021, there were 7560 apparent opioid-related deaths in Canada, which is equivalent to 20 people dying each day, and was greater than the average number of Canadians killed daily in motor vehicle collisions. This number continues to grow, with the PHAC projecting as many as 2400 opioid-related deaths in each quarter of 2022.

The use of Kratom in Southeast Asia has been documented back for at least 150 years and is described both as having a stimulant effect for use in hard day labor when fresh leaves are chewed and an analgesic and relaxing effect if brewed into a tea. In the past decade or more, recognition and the use of kratom has grown in Canada, the United States, and the world at large. Although use has increased, there still remains a lack of research regarding kratom and the various different components within it that are active when taken. One important observation that has been made is that people who take kratom do not see the same respiratory decrease that is often the cause of death and overdose in people who take opiates. This is due to 7-hydroxymitragynine being a partial mu opioid agonist, unlike Fentanyl and oxycodone which are full mu opioid agonists and are known to have depressant effects on respiration.

With so many people affected by opioid use disorder, opioid addiction, and the risk of death from using these substances, research into alternative pain formulations is more than ever necessary. In order to create a medicine that has the potential to truly help people with addictions and those living with chronic pain, it is important to have a deep understanding of how these compounds work in the brain and body. Scientists and doctors have long used deuterated drugs to …….

Source: https://finance.yahoo.com/news/nirvana-life-sciences-inc-deuterates-130000276.html

Leave a Reply

Your email address will not be published.